Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.13 up 1.62% from its previous closing price of $3.08. In other words, the price has increased by $1.62 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
For a deeper understanding of Arbutus Biopharma Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.01. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 21 ’25 when McElhaugh Michael J. bought 246,886 shares for $3.26 per share.
McElhaugh Michael J. bought 53,114 shares of ABUS for $170,098 on Apr 15 ’25. On Mar 31 ’25, another insider, Sofia Michael J., who serves as the Officer of the company, bought 250,000 shares for $3.50 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 93.67 while its Price-to-Book (P/B) ratio in mrq is 7.57.
Stock Price History:
Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.70. The 50-Day Moving Average of the stock is -4.50%, while the 200-Day Moving Average is calculated to be -12.20%.
Shares Statistics:
A total of 191.48M shares are outstanding, with a floating share count of 148.66M. Insiders hold about 22.38% of the company’s shares, while institutions hold 58.79% stake in the company.
